Company Overview and News

 
Intuit (INTU) Beats Q3 Earnings Estimates, Revises Outlook

16h zacks
Intuit Inc. (INTU - Free Report) delivered impressive third-quarter fiscal 2018 results. The company reported non-GAAP income (excluding stock-based compensation, amortization and other one-time items) from continuing operations of $4.82 per share, surpassing the Zacks Consensus Estimate of $4.67. The figure also increased 24% on a year-over-year basis. Quarter in Detail This tax-preparation related software maker reported revenues of $2.

 
TransUnion to Buy iovation, Boost Fraud Identity Services

16h zacks
TransUnion (TRU - Free Report) has inked a deal to acquire Portland, OR-based authentication and fraud prevention solutions provider, iovation, for an undisclosed amount.

 
Here's Why You Should Add Accenture to Your Portfolio Now

2018-05-22 zacks
A wise investment decision involves buying well-performing stocks at the right time while selling those that are at risk. A rise in share price and strong fundamentals signal a stock’s bullish run.

 
Here's Why Interpublic (IPG) Should be in Your Portfolio

2018-05-21 zacks
A prudent investment decision involves buying well-performing stocks at the right time while selling those that are at risk. A rise in share price and strong fundamentals signal a stock’s bullish run.

 
TransUnion (TRU) to Acquire HPS, Boost Healthcare Suite

2018-05-21 zacks
TransUnion’s (TRU - Free Report) subsidiary — TransUnion Healthcare — inked a deal to acquire Healthcare Payment Specialists (“HPS”). Based in Fort Worth, TX, Healthcare Payment Specialists assists healthcare service providers in boosting medical reimbursements. The deal is expected to be closed in the second quarter of 2018, subject to pending regulatory approvals.

 
Here's Why You Should Hold On to Paylocity (PCTY) Stock

2018-05-18 zacks
Paylocity Holding (PCTY - Free Report) has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average positive surprise of 220.1%. With expected long-term earnings per share growth rate of 22% and a market cap of $3.03 billion, it seems to be a stock that investors need to retain in their portfolio if they are looking to reap long-term gains.

 
Is First Trust Rising Dividend Achievers ETF (RDVY) a Hot ETF Right Now?

2018-05-18 zacks
Launched on 01/07/2014, the First Trust Rising Dividend Achievers ETF (RDVY - Free Report) is a smart beta exchange traded fund offering broad exposure to the Large Cap ETFs category of the U.S. equity market.

 
Why Should You Retain Navigant Consulting in Your Portfolio?

2018-05-17 zacks
A prudent investment decision involves buying stocks that have solid prospects and selling those that carry risks. At times, it is rational to hold certain stocks that have enough potential but are weighed down by tough market conditions.

 
Interpublic's Unit Buys Cappuccino, Boosts Digital Content

2018-05-17 zacks
The Interpublic Group of Companies, Inc.’s (IPG - Free Report) subsidiary - Weber Shandwick – completed the acquisition of Cappuccino on May 15. Based in Sao Paulo, Brazil, Cappuccino is a digital marketing and technology agency. The financial terms of the deal have been kept under wraps.

 
Bill Ackman calls for a breakup of United Technologies - MarketWatch

2018-05-17 marketwatch
Billionaire hedge-fund manager Bill Ackman on Thursday called for a breakup of United Technologies Corp. saying the individual businesses are more likely to trade at fair value as independent companies.

 
Why Should You Retain Omnicom (OMC) Stock in Your Portfolio?

2018-05-17 zacks
A prudent investment decision involves buying stocks that have solid prospects and selling those that carry risks. At times, it is rational to hold certain stocks that have enough potential but are weighed down by tough market conditions.

 
TRU or DNB: Which Stock is More Attractive Post Q1 Earnings?

2018-05-17 zacks
The first-quarter reporting cycle has seen strong earnings and revenue growth, which is expected to reach its highest level in seven years.

 
Northrop Grumman: Buy This Growing Military Company For Total Return

2018-05-16 seekingalpha
Northrop Grumman's total return over-performed the Dow average for my 52.0-month test period by 143.48% which is fantastic.

 
Tracking Bill Ackman's Pershing Square Portfolio - Q1 2018 Update

2018-05-16 seekingalpha
The largest three 13F positions are Restaurant Brands International, Chipotle Mexican Grill, and Automatic Data Processing and together they account for around two-thirds of the portfolio.

 
Two More Activist Funds Build Stakes in ADP - WSJ

2018-05-15 wsj
Two activist hedge funds have built small stakes in Automatic Data Processing Inc., according to people familiar with the matter, adding pressure to the payroll-processing firm as it tries to jumpstart growth.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...